Key facts
- Amphista Therapeutics’s last known valuation is $104.0M (Oct 2025).
- It has raised $78.5M; the latest was Later Stage VC ($16.9M) in Oct 2025.
- Notable investors include Scottish Enterprise, SV Health Investors, Forbion, Gilde Healthcare, Novartis Venture Fund — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Amphista Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Amphista Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Amphista Therapeutics
Developer of next-generation targeted protein degradation therapeutics designed to treat a range of diseases. The company's therapeutics advance novel approaches in targeted protein degradation to create a new generation of therapies with improved efficacy and identify the cell's degradation machinery to modulate the abundance of proteins that are responsible for disease progression, enabling healthcare providers to improve the lives of patients.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2017
- Employees
- 65
- Website
- amphista.com/
- Ownership
- Privately Held (backing)
Amphista Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amphista Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amphista Therapeutics in its N-PORT filings yet. We sweep new filings monthly.